Meso scale discovery s plex human il 17a kit

Serum levels of cytokines (TNF-α, IL-17A) were measured in patients by electrochemiluminescence before (guselkumab; n=12, adalimumab; n=11) and 6 months after the treatment with guselkumab (n=5) or adalimumab (n=7). Serum samples were isolated immediately after taking blood from patients and stored in a −80°C freezer; serum samples were not thawed until cytokine measurement. The MESO SCALE DISCOVERY S-PLEX Human IL-17A kit (#K15067L-1, Meso Scale Diagnostics, LLC, Rockville, MD, USA) was used to measure IL-17A (fg/mL), and the U-PLEX Biomarker Group 1 (#K151C3S-1, Meso Scale Diagnostics, LLC, Rockville, MD, USA) was used to measure TNF-α (pg/mL).

In cohorts 1 and 2, serum cytokine (IFN-γ, IL-6, TNF-α, IL-17A, IL-21, IL-22, and IL-23) concentrations were measured. Similarly, these concentrations were also measured in the healthy control (HC) group, matched for age and sex. The concentrations of cytokines at the initiation of bDMARD therapy were measured after a 1-year observation period in all patients in both cohorts. The MESO SCALE DISCOVERY S-PLEX Human IL-17A kit (#K15067L-1, Meso Scale Diagnostics, LLC, Rockville, MD, USA) was used to measure IL-17A (fg/ml), and the U-PLEX Biomarker Group 1 (#K151C3S-1, Meso Scale Diagnostics, LLC, Rockville, MD, USA) was used to measure IFN-γ (pg/ml), IL-6 (pg/ml), TNF-α (pg/ml), IL-21 (pg/ml), IL-22 (pg/ml), and IL-23 (pg/ml) [10 (link)].